NCT06694740View on ClinicalTrials.gov

Effect of Interferon Gamma As a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

170

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

April 30, 2028

Conditions

Post-aggressive ImmunosuppressionAdult Patients Admitted to Intensive Care with Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6Adult Under Mechanical Ventilation, and Presenting an MHLA-DR Less Than 8,000AB/C

Interventions

DRUG

Interferon Gamma 1-b

interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

DRUG

Placebo

Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT06694740 - Effect of Interferon Gamma As a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo | Biotech Hunter | Biotech Hunter